Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B J Roberts

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Cancer Research|May 1, 1984
Anticancer activity of the structurally novel antibiotic Cl-920 and its analoguesW R Leopold, J L Shillis, A E Mertus, et al.
American Journal of Veterinary Research|July 1, 1987
Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in miceR J Yancey, M L Kinney, B J Roberts, et al.
Cancer Treatment Reports|May 1, 1982
Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agentsT H Corbett, B J Roberts, M W Trader, et al.
Archives of Biochemistry and Biophysics|February 1, 1996
Transcriptional inhibition of cytochrome P4502E1 by a synthetic compound, YH439K S Jeong, I J Lee, B J Roberts, et al.
Investigational New Drugs|January 1, 1996
Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude miceM W Kunkel, K E Hook, C T Howard, et al.
Cancer Research|February 1, 1984
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 miceT H Corbett, B J Roberts, W R Leopold, et al.
Molecular Pharmacology|June 1, 1996
Transcriptional induction of the cytochrome P4501A1 gene by a thiazolium compound, YH439I J Lee, K S Jeong, B J Roberts, et al.
Journal of Medicinal Chemistry|December 16, 1997
Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenograftsP W Vincent, A J Bridges, D J Dykes, et al.
Journal of Medicinal Chemistry|March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Cancer Research|May 1, 1984
Anticancer activity of the structurally novel antibiotic Cl-920 and its analoguesW R Leopold, J L Shillis, A E Mertus, et al.
American Journal of Veterinary Research|July 1, 1987
Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in miceR J Yancey, M L Kinney, B J Roberts, et al.
Cancer Treatment Reports|May 1, 1982
Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agentsT H Corbett, B J Roberts, M W Trader, et al.
Archives of Biochemistry and Biophysics|February 1, 1996
Transcriptional inhibition of cytochrome P4502E1 by a synthetic compound, YH439K S Jeong, I J Lee, B J Roberts, et al.
Investigational New Drugs|January 1, 1996
Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude miceM W Kunkel, K E Hook, C T Howard, et al.
Cancer Research|February 1, 1984
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 miceT H Corbett, B J Roberts, W R Leopold, et al.
Molecular Pharmacology|June 1, 1996
Transcriptional induction of the cytochrome P4501A1 gene by a thiazolium compound, YH439I J Lee, K S Jeong, B J Roberts, et al.
Journal of Medicinal Chemistry|December 16, 1997
Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenograftsP W Vincent, A J Bridges, D J Dykes, et al.
Journal of Medicinal Chemistry|March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.
Pageof 5